دورية أكاديمية
أعرض في EDS

Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer.

التفاصيل البيبلوغرافية
العنوان: Androgen receptor agonism in advanced oestrogen receptor-positive breast cancer.
المؤلفون: Chen N; University of Chicago Medicine, Chicago, IL 60637, USA., Nanda R; University of Chicago Medicine, Chicago, IL 60637, USA. Electronic address: rnanda@bsd.uchicago.edu.
المصدر: The Lancet. Oncology [Lancet Oncol] 2024 Mar; Vol. 25 (3), pp. 269-270. Date of Electronic Publication: 2024 Feb 08.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Lancet Pub. Group, c2000-
مواضيع طبية MeSH: Breast Neoplasms*/drug therapy , Breast Neoplasms*/genetics, Humans ; Female ; Receptors, Androgen/genetics ; Receptors, Estrogen
مستخلص: Competing Interests: NC has received consultant fees from Guardant Health, Seagen, Stemline, and GE Health; and research funding from Eli Lilly. RN has received consulting fees from AstraZeneca, BeyondSpring, Daiichi Sankyo, Exact Sciences, Fujifilm, GE, Gilead, Guardant Health, Infinity, iTeos, Merck, Moderna, Novartis, OBI, Oncosec, Pfizer, Sanofi, Seagen, and Stemline; and research funding from Arvinas, AstraZeneca, BMS, Corcept Therapeutics, Genentech/Roche, Gilead, GSK, Merck, Novartis, OBI Pharma, OncoSec, Pfizer, Relay, Seattle Genetics, Sun Pharma, and Taiho.
المشرفين على المادة: 0 (Receptors, Androgen)
0 (Receptors, Estrogen)
تواريخ الأحداث: Date Created: 20240211 Date Completed: 20240304 Latest Revision: 20240304
رمز التحديث: 20240304
DOI: 10.1016/S1470-2045(24)00080-9
PMID: 38342112
قاعدة البيانات: MEDLINE
الوصف
تدمد:1474-5488
DOI:10.1016/S1470-2045(24)00080-9